Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferation

被引:14
作者
Boehler, Torsten [1 ]
Nolting, Jochen [2 ]
Gurragchaa, Purevtseren [2 ]
Lupescu, Adrian [2 ]
Neumayer, Hans-H. [2 ]
Budde, Klemens [2 ]
Kamar, Nassim [3 ]
Klupp, Jochen [4 ]
机构
[1] CHU Rangueil, Inst Louis Bugnard, INSERM, U858, F-31054 Toulouse, France
[2] Humboldt Univ, Dept Nephrol, Berlin, Germany
[3] CHU Rangueil, Dept Nephrol Dialysis & Multiorgan Transplantat, F-31054 Toulouse, France
[4] Humboldt Univ, Dept Surg, Berlin, Germany
关键词
immunosuppression; transplantation; lymphocyte proliferation; cytokines; pharmacodynamics;
D O I
10.1016/j.trim.2007.08.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In order to identify new, immune modulating compounds, aqueous extracts of plants pre-selected on ethno-pharmacological knowledge were screened for inhibitory effects in an anti-CD3 driven lymphocyte proliferation assay (MTT-assay). We found for the extract of the inner bark of Tabebuia avellanedae (Tabebuia) dose dependent and reproducible inhibitory effects on lymphocyte proliferation. We further analyzed Tabebuia in flow cytometry based whole blood T-cell function assays. We found that Tabebuia inhibited dose dependent ConA stimulated T-cell proliferation. Decreased T-lymphocyte proliferation was associated with dose dependent reduction of CD25 and CD71 expression on Tlymphocytes. In contrast Tabebuia exerted no effects on cytokine expression (Il-2 and TNF-alpha) by PMA/Ionomycin stimulated T-lymphocytes. Concentrations of Tabebuia used were not toxic for lymphocytes as verified by trypan blue exclusion assay. Further experiments showed that the immune inhibitory effects by Tabebuia were not mediated by its pharmacological lead compound beta-lapachone and only observed in aqueous but not in ethanol plant extracts. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 19 条
[1]  
Böhler T, 2007, THER DRUG MONIT, V29, P77
[2]   The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation [J].
Böhler, T ;
Waiser, J ;
Budde, K ;
Lichter, S ;
Jauho, A ;
Fritsche, L ;
Korn, A ;
Neumayer, HH .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) :2195-2197
[3]  
de Miranda F G, 2001, BMC Pharmacol, V1, P6
[4]   Immunosuppressive therapy and malignancy in organ transplant recipients - A systematic review [J].
Gutierrez-Dalmau, Alex ;
Campistol, Josep M. .
DRUGS, 2007, 67 (08) :1167-1198
[5]  
Hanson Kimberly, 2006, Expert Rev Anti Infect Ther, V4, P837, DOI 10.1586/14787210.4.5.837
[6]   Overcoming barriers to long-term graft survival [J].
Kaplan, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) :S52-S64
[7]   Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid [J].
Knecht, W ;
Henseling, J ;
Löffler, M .
CHEMICO-BIOLOGICAL INTERACTIONS, 2000, 124 (01) :61-76
[8]   NEW FURANONAPHTHOQUINONES AND OTHER CONSTITUENTS OF TABEBUIA-AVELLANEDAE AND THEIR IMMUNOMODULATING ACTIVITIES INVITRO [J].
KREHER, B ;
LOTTER, H ;
CORDELL, GA ;
WAGNER, H .
PLANTA MEDICA, 1988, (06) :562-563
[9]  
LI CJ, 1993, J BIOL CHEM, V268, P22463
[10]   Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation [J].
Morales, Jose Maria ;
Dominguez-Gil, Beatriz .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 :S296-S303